Company announced positive interim clinical trial data with 100% complete response rate, is advancing its lead CAR-T candidate toward potential registrational trials, and continues to expand its pipeline with multiple ongoing studies. The presentation of updated data at a major scientific conference demonstrates progress in development.
Company announced positive interim clinical trial data with 100% complete response rates, secured a manufacturing partnership with a reputable CDMO, and is on track for U.S. registrational study initiation in 2026, demonstrating strong clinical progress and operational advancement.
Articles that tag TPST but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
